Year: 2020

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.To access the live webcast presentation, or the subsequent archived recording, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.About Ziopharm Oncology, Inc. Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline...

West Palm Beach, FL, Nov. 13, 2020 (GLOBE NEWSWIRE) — USA Equities Corp. (OTCQB: USAQ), and its wholly owned subsidiary Medical Practice Income, a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce today, equity research firm, Litchfield Hills Research LLC released its first analyst coverage report on USAQ, rating the Company a “Buy” under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share.As of the end of its last trading day, USAQ’s shares closed at $.62 per share.“We are pleased Litchfield Hills Research initiated research and analyst coverage of USAQ. Litchfield has shown a keen interest in our digital and virtual medicine technologies and will continue to cover our company in the future,” said Troy...

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/jeff141/anab/1804050A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for 90 days following the event.About AnaptysBioAnaptysBio...

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that President & CEO Gerald Commissiong has provided a corporate update to the shareholders:Dear Shareholder,We would like to thank you for continued support as we execute on the vision we laid out in the first half of 2020, transitioning the Company from a cancer and Alzheimer’s-focused R&D diagnostics company into a commercial organization focused on providing comprehensive solutions to address the United States’ biggest challenges in testing, tracing and immune support in...

– Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins1–– Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and females* vs. placebo2–ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced results of pooled data from four of the company’s Phase 3 trials were presented at the virtual American Heart Association Scientific Sessions 2020 (AHA 2020). Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.     “Women are half of the population, and nearly 10 million patients...

NEWARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) — Esports Entertainment Group, Inc. (NasdaqCM: GMBL, GMBLW) (or the “Company”), a licensed online gambling company with a focus on esports wagering and 18+ gaming, will host a conference call and webcast on Monday, November 16, 2020 at 4:30 p.m. ET to answer questions about the Company’s operational and financial highlights for the third quarter of 2020 and recent developments.For interested individuals unable to join the conference call, a dial-in replay of the call will be available until November 30, 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 10011948.About Esports Entertainment GroupEsports Entertainment Group, Inc. is a licensed online gambling company with a specific focus on esports...

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock offered in the public offering.Cantor Fitzgerald & Co. is acting as lead bookrunning manager for the offering. H.C. Wainwright & Co. is acting as joint bookrunning manager for the offering. Maxim Group LLC is acting as a co-manager for the offering.The...

Company annoucement nr. 47Fredericia, November 13th. 2020Board member Jes Nordentoft, has chosen to resign from the board per. 25.11.2020.About Waturu Holding A/SWaturu Holding A/S is a Greentech company, which develops innovative water technology for heating ortreating water, with the focus on ensuring bacteria-free water and reducing water and energy consumptionfor heating hot water in properties and thus ensuring CO2 savings. Waturu Holding A/S is a majorshareholder in the medical company Watgen Medical A/S and in the technology company Aquaturu A/S.Further information:CEO Toke Reedtz, cell.: +45 5188 1262, e-mail: toke@waturu.comWaturu Holding A/SSjællandsgade 327100 VejleFinancial reports:www.waturu.com/documentsFurther press related news:www.linkedin.com/company/waturu/www.facebook.com/WaturuDenmark/